15001 Background: BIBF1120 is a triple angiokinase inhibitor (VEGFR1–3, PDGFR and FGFR). BIBW2992 is an inhibitor of EGFR and HER2. Combined blockade of these targets may have additive or synergistic effects on tumour response. Methods: BIBF1120 was administered orally twice daily at 250 mg on days 1 to 7, followed by BIBW2992 at 50 mg once daily on days 8–14. Sequential administration was repeated in 4 weeks (wks) cycles for at least 24 wks. Patients (pts) were eligible for repeated treatment courses in the absence of progression of disease (PD). Objective response rate (OR) was used as primary endpoint. Plasma samples were taken to determine pharmakokinetics and potential drug-drug interactions between BIBF 1120 and BIBW2992. Results: A total of 46 (28 male/18 female) pts with a median age of 58.5 years (range 42–79) were treated for median of 9 wks (range: 2–32). 45 pts (97.8%) previously received at least two lines of treatment, 38 (82.6%) three lines and 26 (56.5%) more than three lines. Twenty-four pts (52.2%) previously received bevacizumab and 41 (89.1%) cetuximab. The best response observed was stable disease in 20 pts (43.5%) and PD in 26 pts (56.5%). Median Progression free survival (PFS) was 1.8 months and median overall survival (OS) was 5.1 months. 43 pts (93.5%) experienced at least one drug-related adverse event. The most common were diarrhoea as reported in 37 pts (80.4%), with 2.2% grade 4 and 13% grade 3 events. Nausea was prevalent in 20 pts (43.5%), with 2.2% grade 3 and vomiting in 15 pts (32.6%) with 4.3% grade 3. Rash was experienced by 19 pts (41.3%). Asthenia was reported in 22 pts (47.8%) with 8.7% grade 3. Increased alanine aminotransferase grade 3 was observed in 4 pts (8.7%). Conclusions: The sequential weekly administration of BIBF1120 and BIBW 2992 has an acceptable safety profile.The combination treatment shows no OR in heavily pre-treated patients with metastatic colorectal cancer. Other schedules of administration warrant further evaluation. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Boehringer Ingelheim Amgen, Pfizer Oncology, Roche Amgen, Boehringer Ingelheim, Merck, Roche, sanofi-aventis